The Economic and Public Health Assessment Committee (CEESP) was introduced in 2012 as a specialised committee affiliated with the ‘Haute Autorité de Santé’ (HAS) in charge of providing health economic opinions. This research provides a forward-looking analysis of health economic assessment of pharmaceuticals in France and its impact on market access of drugs. It also provides likely directions of the future French HTA organisation and processes.